Charles Quick
Concepts (404)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Endometrial Neoplasms | 18 | 2021 | 137 | 4.480 |
Why?
| Vulvar Neoplasms | 6 | 2024 | 58 | 2.760 |
Why?
| Carcinoma, Squamous Cell | 9 | 2024 | 330 | 2.200 |
Why?
| Carcinoma in Situ | 7 | 2022 | 73 | 1.940 |
Why?
| Uterine Neoplasms | 10 | 2023 | 60 | 1.940 |
Why?
| Carcinoma, Endometrioid | 6 | 2021 | 38 | 1.610 |
Why?
| Adenocarcinoma | 10 | 2024 | 402 | 1.550 |
Why?
| Tumor Suppressor Protein p53 | 3 | 2024 | 213 | 1.480 |
Why?
| PAX2 Transcription Factor | 7 | 2015 | 22 | 1.430 |
Why?
| Immunohistochemistry | 16 | 2024 | 972 | 1.320 |
Why?
| Uterine Cervical Neoplasms | 7 | 2024 | 276 | 1.180 |
Why?
| Ovarian Neoplasms | 10 | 2024 | 450 | 1.170 |
Why?
| Observer Variation | 4 | 2024 | 136 | 1.130 |
Why?
| Endometrial Hyperplasia | 4 | 2019 | 14 | 1.130 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2024 | 60 | 1.080 |
Why?
| Stromal Cells | 2 | 2016 | 72 | 1.020 |
Why?
| Female | 66 | 2024 | 26576 | 0.920 |
Why?
| Sarcoma, Alveolar Soft Part | 1 | 2023 | 1 | 0.890 |
Why?
| Cannabidiol | 5 | 2024 | 35 | 0.880 |
Why?
| Myometrium | 2 | 2013 | 14 | 0.850 |
Why?
| Endometrium | 6 | 2023 | 40 | 0.820 |
Why?
| Adenocarcinoma, Clear Cell | 6 | 2019 | 34 | 0.770 |
Why?
| Precancerous Conditions | 3 | 2019 | 83 | 0.750 |
Why?
| Aged, 80 and over | 20 | 2024 | 3138 | 0.720 |
Why?
| Middle Aged | 35 | 2024 | 12293 | 0.700 |
Why?
| Plant Extracts | 5 | 2024 | 166 | 0.690 |
Why?
| Cystadenocarcinoma, Serous | 4 | 2013 | 71 | 0.690 |
Why?
| Aged | 30 | 2024 | 9449 | 0.680 |
Why?
| Humans | 69 | 2024 | 49929 | 0.680 |
Why?
| Peripheral Nerves | 2 | 2015 | 48 | 0.620 |
Why?
| Mutation | 9 | 2024 | 1292 | 0.590 |
Why?
| Placenta | 6 | 2021 | 129 | 0.570 |
Why?
| Cervix Uteri | 2 | 2017 | 42 | 0.560 |
Why?
| Epithelial-Mesenchymal Transition | 2 | 2016 | 49 | 0.560 |
Why?
| Adult | 31 | 2024 | 13356 | 0.560 |
Why?
| Cannabis | 5 | 2024 | 144 | 0.540 |
Why?
| Adenosarcoma | 1 | 2016 | 3 | 0.540 |
Why?
| Polyps | 1 | 2016 | 20 | 0.530 |
Why?
| Uterine Cervical Dysplasia | 1 | 2016 | 49 | 0.520 |
Why?
| Lymphatic Metastasis | 6 | 2019 | 226 | 0.500 |
Why?
| Neoplasm Staging | 9 | 2024 | 749 | 0.500 |
Why?
| Fibroma | 1 | 2015 | 39 | 0.500 |
Why?
| Papillomavirus Infections | 3 | 2024 | 167 | 0.500 |
Why?
| Fallopian Tubes | 2 | 2012 | 22 | 0.500 |
Why?
| Tumor Microenvironment | 4 | 2021 | 221 | 0.490 |
Why?
| Prognosis | 11 | 2024 | 1957 | 0.450 |
Why?
| Neoplasm Invasiveness | 6 | 2019 | 268 | 0.440 |
Why?
| Pelvic Neoplasms | 1 | 2011 | 14 | 0.390 |
Why?
| Uterus | 3 | 2023 | 87 | 0.380 |
Why?
| Lymphocytes, Tumor-Infiltrating | 3 | 2021 | 75 | 0.380 |
Why?
| Ejaculatory Ducts | 1 | 2010 | 3 | 0.360 |
Why?
| Seminal Vesicles | 1 | 2010 | 13 | 0.350 |
Why?
| Neoplasm Recurrence, Local | 4 | 2015 | 626 | 0.350 |
Why?
| Spectrum Analysis, Raman | 2 | 2021 | 54 | 0.350 |
Why?
| Reproducibility of Results | 5 | 2024 | 1182 | 0.350 |
Why?
| Prostate | 1 | 2010 | 117 | 0.330 |
Why?
| Bromcresol Purple | 1 | 2009 | 3 | 0.330 |
Why?
| Electrophoresis, Capillary | 1 | 2009 | 9 | 0.330 |
Why?
| Mice, Inbred C57BL | 6 | 2024 | 1777 | 0.320 |
Why?
| Serum Albumin | 1 | 2009 | 58 | 0.320 |
Why?
| Human papillomavirus 16 | 2 | 2021 | 44 | 0.320 |
Why?
| Methionine | 2 | 2020 | 133 | 0.310 |
Why?
| beta Catenin | 2 | 2021 | 101 | 0.310 |
Why?
| Disease Progression | 4 | 2020 | 820 | 0.300 |
Why?
| Predictive Value of Tests | 5 | 2024 | 907 | 0.300 |
Why?
| Mice | 15 | 2024 | 5658 | 0.300 |
Why?
| Diabetes Mellitus | 2 | 2023 | 279 | 0.300 |
Why?
| Genital Neoplasms, Female | 2 | 2018 | 41 | 0.290 |
Why?
| Papillomavirus Vaccines | 2 | 2021 | 67 | 0.290 |
Why?
| Anus Neoplasms | 2 | 2018 | 24 | 0.290 |
Why?
| Cell Proliferation | 4 | 2021 | 986 | 0.280 |
Why?
| Metaplasia | 2 | 2019 | 15 | 0.280 |
Why?
| Antigens, CD | 2 | 2019 | 215 | 0.280 |
Why?
| Diagnosis, Differential | 8 | 2020 | 1037 | 0.270 |
Why?
| Prostatic Neoplasms | 1 | 2010 | 391 | 0.270 |
Why?
| Colitis | 2 | 2020 | 51 | 0.260 |
Why?
| Polyethylene Glycols | 2 | 2017 | 85 | 0.260 |
Why?
| Melanoma | 2 | 2020 | 281 | 0.260 |
Why?
| Neoplasm Grading | 5 | 2021 | 123 | 0.260 |
Why?
| Hypertension | 2 | 2021 | 531 | 0.250 |
Why?
| Chi-Square Distribution | 2 | 2016 | 275 | 0.250 |
Why?
| Gold | 2 | 2017 | 129 | 0.250 |
Why?
| Proteomics | 3 | 2017 | 292 | 0.250 |
Why?
| Nanoparticles | 2 | 2017 | 151 | 0.240 |
Why?
| Aspartic Acid Endopeptidases | 2 | 2015 | 16 | 0.240 |
Why?
| Young Adult | 7 | 2024 | 4031 | 0.240 |
Why?
| Retrospective Studies | 11 | 2020 | 6124 | 0.230 |
Why?
| Racemases and Epimerases | 2 | 2015 | 17 | 0.230 |
Why?
| Sex Cord-Gonadal Stromal Tumors | 1 | 2024 | 3 | 0.230 |
Why?
| Animals | 16 | 2024 | 13100 | 0.230 |
Why?
| Neuroendocrine Tumors | 1 | 2024 | 22 | 0.230 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2024 | 23 | 0.230 |
Why?
| DNA Mutational Analysis | 3 | 2024 | 176 | 0.230 |
Why?
| Head and Neck Neoplasms | 2 | 2019 | 281 | 0.230 |
Why?
| Kidney Neoplasms | 2 | 2018 | 172 | 0.220 |
Why?
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2024 | 40 | 0.220 |
Why?
| Chlamydia muridarum | 1 | 2024 | 40 | 0.220 |
Why?
| Homeodomain Proteins | 1 | 2024 | 83 | 0.220 |
Why?
| Lung Neoplasms | 2 | 2019 | 602 | 0.220 |
Why?
| Endometriosis | 1 | 2023 | 14 | 0.210 |
Why?
| Gynecology | 2 | 2020 | 49 | 0.210 |
Why?
| Chlamydia Infections | 1 | 2024 | 75 | 0.210 |
Why?
| Adenocarcinoma, Sebaceous | 1 | 2022 | 7 | 0.210 |
Why?
| Sebaceous Gland Neoplasms | 1 | 2022 | 16 | 0.210 |
Why?
| CD4-Positive T-Lymphocytes | 1 | 2024 | 157 | 0.200 |
Why?
| Fallopian Tube Neoplasms | 2 | 2012 | 14 | 0.200 |
Why?
| Immunotherapy | 2 | 2021 | 235 | 0.200 |
Why?
| Gestational Trophoblastic Disease | 2 | 2012 | 2 | 0.200 |
Why?
| CTLA-4 Antigen | 1 | 2021 | 23 | 0.190 |
Why?
| Genotype | 2 | 2021 | 539 | 0.190 |
Why?
| Fetal Membranes, Premature Rupture | 1 | 2021 | 22 | 0.190 |
Why?
| Estrogens | 2 | 2023 | 222 | 0.190 |
Why?
| Oncogene Fusion | 1 | 2021 | 4 | 0.190 |
Why?
| PTEN Phosphohydrolase | 3 | 2020 | 53 | 0.190 |
Why?
| Leiomyosarcoma | 1 | 2021 | 23 | 0.190 |
Why?
| Diabetes, Gestational | 1 | 2021 | 51 | 0.190 |
Why?
| Transcription Factors | 3 | 2020 | 565 | 0.190 |
Why?
| Cancer Vaccines | 1 | 2021 | 78 | 0.180 |
Why?
| Carcinosarcoma | 2 | 2017 | 18 | 0.180 |
Why?
| Infant, Small for Gestational Age | 1 | 2020 | 32 | 0.180 |
Why?
| Neoplasms, Experimental | 1 | 2020 | 111 | 0.180 |
Why?
| Carcinoma, Papillary | 1 | 2020 | 49 | 0.180 |
Why?
| Carcinoma, Transitional Cell | 1 | 2020 | 52 | 0.170 |
Why?
| Pregnancy in Diabetics | 1 | 2020 | 27 | 0.170 |
Why?
| Colonic Neoplasms | 1 | 2021 | 158 | 0.170 |
Why?
| Carcinoma, Signet Ring Cell | 1 | 2019 | 14 | 0.170 |
Why?
| Carcinoma, Lewis Lung | 1 | 2019 | 9 | 0.170 |
Why?
| Radiotherapy | 1 | 2020 | 124 | 0.170 |
Why?
| Dermatology | 1 | 2020 | 52 | 0.170 |
Why?
| Placenta Diseases | 1 | 2019 | 14 | 0.170 |
Why?
| Pregnancy Complications, Neoplastic | 1 | 2019 | 24 | 0.170 |
Why?
| Carcinoma, Renal Cell | 2 | 2018 | 101 | 0.170 |
Why?
| Skin Diseases | 1 | 2020 | 114 | 0.170 |
Why?
| Premature Birth | 1 | 2021 | 143 | 0.170 |
Why?
| Hepatic Veno-Occlusive Disease | 1 | 2019 | 9 | 0.170 |
Why?
| Odds Ratio | 3 | 2015 | 548 | 0.160 |
Why?
| Melanoma, Experimental | 1 | 2019 | 40 | 0.160 |
Why?
| Hodgkin Disease | 1 | 2019 | 44 | 0.160 |
Why?
| DNA Polymerase II | 1 | 2019 | 9 | 0.160 |
Why?
| T-Lymphocytes | 1 | 2021 | 328 | 0.160 |
Why?
| DNA Mismatch Repair | 1 | 2019 | 16 | 0.160 |
Why?
| Fetal Diseases | 1 | 2019 | 60 | 0.160 |
Why?
| Inflammation | 2 | 2020 | 603 | 0.160 |
Why?
| Sarcoma | 1 | 2020 | 65 | 0.160 |
Why?
| Monocytes | 1 | 2019 | 131 | 0.160 |
Why?
| Pregnancy | 7 | 2021 | 2468 | 0.160 |
Why?
| Urinary Bladder Neoplasms | 1 | 2020 | 158 | 0.160 |
Why?
| Metformin | 1 | 2020 | 63 | 0.160 |
Why?
| Methionine Adenosyltransferase | 1 | 2018 | 19 | 0.160 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2019 | 124 | 0.160 |
Why?
| Logistic Models | 3 | 2015 | 896 | 0.150 |
Why?
| Nuclear Proteins | 1 | 2020 | 242 | 0.150 |
Why?
| Disease Models, Animal | 6 | 2020 | 1411 | 0.150 |
Why?
| Radiation Tolerance | 1 | 2019 | 83 | 0.150 |
Why?
| Hypoglycemic Agents | 1 | 2020 | 169 | 0.150 |
Why?
| Neural Cell Adhesion Molecule L1 | 1 | 2017 | 1 | 0.150 |
Why?
| Rhabdomyosarcoma | 1 | 2018 | 12 | 0.150 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2018 | 40 | 0.150 |
Why?
| DNA Helicases | 1 | 2020 | 144 | 0.150 |
Why?
| Hepatocytes | 1 | 2019 | 179 | 0.150 |
Why?
| Intestinal Mucosa | 2 | 2020 | 215 | 0.150 |
Why?
| Pathology, Molecular | 1 | 2017 | 22 | 0.150 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 66 | 0.150 |
Why?
| Biopsy | 5 | 2020 | 591 | 0.150 |
Why?
| Tumor Necrosis Factor-alpha | 2 | 2019 | 388 | 0.150 |
Why?
| Liver | 3 | 2024 | 1106 | 0.150 |
Why?
| Pregnancy Complications | 1 | 2021 | 363 | 0.140 |
Why?
| Osteosarcoma | 1 | 2017 | 45 | 0.140 |
Why?
| Neoplastic Cells, Circulating | 1 | 2017 | 74 | 0.140 |
Why?
| Gene Expression Profiling | 2 | 2019 | 1028 | 0.140 |
Why?
| Vimentin | 1 | 2016 | 32 | 0.140 |
Why?
| Time Factors | 3 | 2021 | 2891 | 0.130 |
Why?
| Papillomaviridae | 1 | 2017 | 102 | 0.130 |
Why?
| Acetaminophen | 1 | 2019 | 275 | 0.130 |
Why?
| DNA-Binding Proteins | 2 | 2016 | 424 | 0.130 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 409 | 0.130 |
Why?
| Cadherins | 1 | 2016 | 64 | 0.130 |
Why?
| Viral Load | 1 | 2016 | 76 | 0.130 |
Why?
| Skin Neoplasms | 1 | 2020 | 487 | 0.120 |
Why?
| Hepatocyte Nuclear Factor 1-beta | 1 | 2015 | 5 | 0.120 |
Why?
| Neoplasms, Muscle Tissue | 1 | 2015 | 12 | 0.120 |
Why?
| Malate Dehydrogenase | 1 | 2014 | 9 | 0.120 |
Why?
| Classification | 1 | 2015 | 14 | 0.120 |
Why?
| Colposcopy | 1 | 2015 | 18 | 0.120 |
Why?
| Class I Phosphatidylinositol 3-Kinases | 3 | 2024 | 17 | 0.120 |
Why?
| Lipogenesis | 1 | 2014 | 29 | 0.120 |
Why?
| Flow Cytometry | 1 | 2017 | 470 | 0.120 |
Why?
| World Health Organization | 1 | 2015 | 48 | 0.120 |
Why?
| Mice, Inbred BALB C | 3 | 2021 | 296 | 0.120 |
Why?
| Cytosol | 1 | 2014 | 81 | 0.120 |
Why?
| Histones | 1 | 2016 | 295 | 0.120 |
Why?
| Adolescent | 4 | 2024 | 6417 | 0.120 |
Why?
| Neoplasm, Residual | 1 | 2015 | 157 | 0.120 |
Why?
| Mammary Neoplasms, Experimental | 1 | 2015 | 121 | 0.120 |
Why?
| Obesity | 1 | 2022 | 1096 | 0.120 |
Why?
| Multiple Myeloma | 1 | 2009 | 2916 | 0.120 |
Why?
| High-Throughput Nucleotide Sequencing | 3 | 2021 | 168 | 0.110 |
Why?
| Antineoplastic Agents | 2 | 2021 | 1175 | 0.110 |
Why?
| Gastrointestinal Tract | 1 | 2014 | 101 | 0.110 |
Why?
| Male | 10 | 2024 | 25454 | 0.110 |
Why?
| Intestines | 1 | 2014 | 169 | 0.110 |
Why?
| Oncogenes | 1 | 2013 | 57 | 0.110 |
Why?
| Cell Line, Tumor | 4 | 2020 | 1388 | 0.110 |
Why?
| Patient Selection | 1 | 2015 | 254 | 0.110 |
Why?
| Clusterin | 1 | 2012 | 6 | 0.110 |
Why?
| Membrane Proteins | 1 | 2015 | 347 | 0.110 |
Why?
| Risk Factors | 3 | 2015 | 3605 | 0.100 |
Why?
| Pancreatic Neoplasms | 1 | 2015 | 209 | 0.100 |
Why?
| Histocytochemistry | 1 | 2012 | 47 | 0.100 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2012 | 22 | 0.100 |
Why?
| Strongyloidiasis | 1 | 2012 | 10 | 0.100 |
Why?
| Follow-Up Studies | 2 | 2016 | 2177 | 0.100 |
Why?
| Treatment Outcome | 3 | 2021 | 5178 | 0.100 |
Why?
| Cytomegalovirus Infections | 1 | 2012 | 35 | 0.100 |
Why?
| Prednisone | 1 | 2012 | 100 | 0.100 |
Why?
| Tissue Inhibitor of Metalloproteinases | 1 | 2011 | 11 | 0.100 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2012 | 183 | 0.100 |
Why?
| Teratoma | 1 | 2011 | 25 | 0.090 |
Why?
| Matrix Metalloproteinases | 1 | 2011 | 47 | 0.090 |
Why?
| Adenoma, Oxyphilic | 1 | 2010 | 11 | 0.090 |
Why?
| Image Processing, Computer-Assisted | 1 | 2012 | 242 | 0.090 |
Why?
| Sensitivity and Specificity | 3 | 2020 | 858 | 0.090 |
Why?
| Phenotype | 3 | 2019 | 728 | 0.090 |
Why?
| Tissue Array Analysis | 3 | 2015 | 45 | 0.090 |
Why?
| Glucocorticoids | 1 | 2012 | 229 | 0.090 |
Why?
| Tumor Cells, Cultured | 2 | 2021 | 462 | 0.080 |
Why?
| Epigenesis, Genetic | 1 | 2012 | 370 | 0.080 |
Why?
| Pregnancy Outcome | 2 | 2021 | 205 | 0.080 |
Why?
| Infant, Newborn | 3 | 2021 | 2729 | 0.080 |
Why?
| Phosphatidylinositol 3-Kinases | 2 | 2024 | 139 | 0.080 |
Why?
| Pilot Projects | 2 | 2023 | 702 | 0.080 |
Why?
| Necrosis | 2 | 2024 | 175 | 0.080 |
Why?
| Telemedicine | 1 | 2015 | 465 | 0.080 |
Why?
| Cell Differentiation | 2 | 2024 | 649 | 0.080 |
Why?
| Hysterectomy | 2 | 2021 | 88 | 0.080 |
Why?
| Cell Nucleus | 2 | 2021 | 186 | 0.070 |
Why?
| Societies, Medical | 2 | 2019 | 177 | 0.070 |
Why?
| Host-Pathogen Interactions | 2 | 2021 | 136 | 0.070 |
Why?
| Neoplasms | 1 | 2017 | 1234 | 0.070 |
Why?
| Gene Expression Regulation | 3 | 2023 | 964 | 0.070 |
Why?
| Consensus | 2 | 2020 | 155 | 0.070 |
Why?
| Ventricular Pressure | 1 | 2006 | 16 | 0.070 |
Why?
| Isoproterenol | 1 | 2006 | 56 | 0.070 |
Why?
| Terminology as Topic | 2 | 2018 | 63 | 0.070 |
Why?
| Kaplan-Meier Estimate | 2 | 2018 | 463 | 0.070 |
Why?
| Serum Response Factor | 1 | 2006 | 40 | 0.070 |
Why?
| Combined Modality Therapy | 2 | 2020 | 638 | 0.070 |
Why?
| Kidney | 1 | 2010 | 672 | 0.070 |
Why?
| Practice Guidelines as Topic | 2 | 2019 | 458 | 0.060 |
Why?
| Neoplasm Metastasis | 2 | 2018 | 235 | 0.060 |
Why?
| Cytokines | 2 | 2020 | 607 | 0.060 |
Why?
| Cells, Cultured | 2 | 2021 | 1587 | 0.060 |
Why?
| Proportional Hazards Models | 2 | 2017 | 404 | 0.060 |
Why?
| Chromatography, Liquid | 2 | 2016 | 225 | 0.060 |
Why?
| Bilirubin | 1 | 2024 | 40 | 0.060 |
Why?
| Tandem Mass Spectrometry | 2 | 2016 | 227 | 0.060 |
Why?
| Dose-Response Relationship, Drug | 2 | 2019 | 1354 | 0.060 |
Why?
| Species Specificity | 1 | 2024 | 193 | 0.060 |
Why?
| Heart | 1 | 2006 | 336 | 0.060 |
Why?
| Steroids | 1 | 2024 | 56 | 0.060 |
Why?
| Th1 Cells | 1 | 2024 | 53 | 0.060 |
Why?
| Interleukin-10 | 1 | 2024 | 83 | 0.060 |
Why?
| Phylogeny | 1 | 2024 | 234 | 0.050 |
Why?
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 824 | 0.050 |
Why?
| Government Agencies | 1 | 2022 | 14 | 0.050 |
Why?
| Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 65 | 0.050 |
Why?
| Hemorrhage | 1 | 2024 | 194 | 0.050 |
Why?
| Choriocarcinoma | 2 | 2012 | 7 | 0.050 |
Why?
| Genes, T-Cell Receptor | 1 | 2021 | 5 | 0.050 |
Why?
| Uterine Hemorrhage | 1 | 2021 | 8 | 0.050 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2021 | 24 | 0.050 |
Why?
| Parturition | 1 | 2021 | 49 | 0.050 |
Why?
| Phthalazines | 1 | 2021 | 20 | 0.050 |
Why?
| Remission Induction | 1 | 2021 | 205 | 0.050 |
Why?
| Quinazolines | 1 | 2021 | 32 | 0.050 |
Why?
| Lymphocyte Activation | 1 | 2021 | 171 | 0.050 |
Why?
| Vulva | 1 | 2020 | 17 | 0.050 |
Why?
| Taurine | 1 | 2020 | 14 | 0.050 |
Why?
| Research Report | 1 | 2020 | 16 | 0.050 |
Why?
| Metabolic Networks and Pathways | 1 | 2021 | 90 | 0.050 |
Why?
| Herb-Drug Interactions | 1 | 2020 | 31 | 0.050 |
Why?
| Mucin-2 | 1 | 2020 | 7 | 0.040 |
Why?
| Toxicity Tests | 1 | 2020 | 54 | 0.040 |
Why?
| Alkaline Phosphatase | 1 | 2020 | 94 | 0.040 |
Why?
| Risk | 1 | 2021 | 314 | 0.040 |
Why?
| Molecular Targeted Therapy | 1 | 2021 | 121 | 0.040 |
Why?
| Piperazines | 1 | 2021 | 118 | 0.040 |
Why?
| United States | 3 | 2016 | 4883 | 0.040 |
Why?
| Chemokines | 1 | 2020 | 75 | 0.040 |
Why?
| Birth Weight | 1 | 2020 | 104 | 0.040 |
Why?
| Preoperative Period | 1 | 2020 | 47 | 0.040 |
Why?
| Chorionic Villi | 1 | 2019 | 3 | 0.040 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 579 | 0.040 |
Why?
| Kruppel-Like Transcription Factors | 1 | 2020 | 35 | 0.040 |
Why?
| Endothelium | 1 | 2019 | 37 | 0.040 |
Why?
| Colon | 1 | 2020 | 96 | 0.040 |
Why?
| Pyrimidines | 1 | 2021 | 192 | 0.040 |
Why?
| Mice, Transgenic | 2 | 2014 | 543 | 0.040 |
Why?
| Chest Pain | 1 | 2019 | 55 | 0.040 |
Why?
| Receptors, Progesterone | 1 | 2020 | 63 | 0.040 |
Why?
| Ultrasonography, Doppler, Color | 1 | 2019 | 31 | 0.040 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2019 | 61 | 0.040 |
Why?
| Cytochrome P-450 Enzyme System | 1 | 2020 | 194 | 0.040 |
Why?
| Glutamine | 1 | 2020 | 169 | 0.040 |
Why?
| Dyspnea | 1 | 2019 | 74 | 0.040 |
Why?
| Estrogen Receptor alpha | 1 | 2020 | 86 | 0.040 |
Why?
| Liver Function Tests | 1 | 2019 | 45 | 0.040 |
Why?
| Fatal Outcome | 1 | 2019 | 194 | 0.040 |
Why?
| Mice, Inbred Strains | 1 | 2019 | 160 | 0.040 |
Why?
| Drug Synergism | 1 | 2019 | 152 | 0.040 |
Why?
| Gestational Age | 1 | 2020 | 386 | 0.040 |
Why?
| Imaging, Three-Dimensional | 1 | 2019 | 152 | 0.040 |
Why?
| Mice, Nude | 1 | 2019 | 252 | 0.040 |
Why?
| Xenograft Model Antitumor Assays | 1 | 2019 | 212 | 0.040 |
Why?
| Nephrectomy | 1 | 2018 | 81 | 0.040 |
Why?
| Mullerian Ducts | 1 | 2018 | 4 | 0.040 |
Why?
| Wolffian Ducts | 1 | 2018 | 2 | 0.040 |
Why?
| Mutation Rate | 1 | 2018 | 36 | 0.040 |
Why?
| Lymph Node Excision | 1 | 2019 | 138 | 0.040 |
Why?
| Ultrasonography, Prenatal | 1 | 2019 | 160 | 0.040 |
Why?
| Cell Lineage | 1 | 2018 | 83 | 0.040 |
Why?
| Mixed Tumor, Mullerian | 1 | 2017 | 3 | 0.040 |
Why?
| DNA Copy Number Variations | 1 | 2018 | 108 | 0.040 |
Why?
| Skin | 1 | 2020 | 415 | 0.040 |
Why?
| Anal Canal | 1 | 2017 | 21 | 0.030 |
Why?
| Macrophages | 1 | 2019 | 361 | 0.030 |
Why?
| Dietary Supplements | 1 | 2020 | 437 | 0.030 |
Why?
| Transcriptome | 1 | 2019 | 312 | 0.030 |
Why?
| Child | 2 | 2024 | 6849 | 0.030 |
Why?
| Lymph Nodes | 1 | 2019 | 257 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2017 | 450 | 0.030 |
Why?
| Matrix Attachment Region Binding Proteins | 1 | 2017 | 35 | 0.030 |
Why?
| Telomerase | 1 | 2016 | 26 | 0.030 |
Why?
| Vaccines, Subunit | 1 | 2016 | 15 | 0.030 |
Why?
| Ontario | 1 | 2016 | 49 | 0.030 |
Why?
| Mesonephros | 1 | 2016 | 1 | 0.030 |
Why?
| Diet | 1 | 2020 | 553 | 0.030 |
Why?
| Signal Transduction | 1 | 2023 | 1608 | 0.030 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2016 | 82 | 0.030 |
Why?
| Anion Exchange Protein 1, Erythrocyte | 1 | 2015 | 8 | 0.030 |
Why?
| Extracellular Fluid | 1 | 2015 | 14 | 0.030 |
Why?
| Antiporters | 1 | 2015 | 19 | 0.030 |
Why?
| Leukocytes, Mononuclear | 1 | 2016 | 112 | 0.030 |
Why?
| S100 Proteins | 1 | 2015 | 34 | 0.030 |
Why?
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2015 | 63 | 0.030 |
Why?
| Cell Count | 1 | 2015 | 147 | 0.030 |
Why?
| Cell Hypoxia | 1 | 2015 | 82 | 0.030 |
Why?
| Pressure | 1 | 2015 | 105 | 0.030 |
Why?
| Drug Evaluation, Preclinical | 1 | 2015 | 145 | 0.030 |
Why?
| Blood Vessels | 1 | 2015 | 71 | 0.030 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 51 | 0.030 |
Why?
| Genetic Predisposition to Disease | 1 | 2018 | 508 | 0.030 |
Why?
| Random Allocation | 1 | 2015 | 285 | 0.030 |
Why?
| Immunoenzyme Techniques | 1 | 2014 | 141 | 0.030 |
Why?
| Prospective Studies | 1 | 2020 | 2345 | 0.030 |
Why?
| Proteome | 1 | 2016 | 153 | 0.030 |
Why?
| Radiotherapy Dosage | 1 | 2015 | 246 | 0.030 |
Why?
| Apoptosis | 1 | 2020 | 1092 | 0.030 |
Why?
| Likelihood Functions | 1 | 2014 | 54 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 181 | 0.030 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2015 | 256 | 0.030 |
Why?
| Anti-Bacterial Agents | 1 | 2019 | 742 | 0.030 |
Why?
| Multivariate Analysis | 1 | 2015 | 579 | 0.030 |
Why?
| Vaccination | 1 | 2016 | 275 | 0.030 |
Why?
| Genes, erbB-1 | 1 | 2013 | 8 | 0.030 |
Why?
| Lipid Metabolism | 1 | 2014 | 175 | 0.030 |
Why?
| Gene Frequency | 1 | 2013 | 96 | 0.030 |
Why?
| Adiposity | 1 | 2014 | 129 | 0.030 |
Why?
| SEER Program | 1 | 2013 | 93 | 0.030 |
Why?
| Communication | 1 | 2015 | 247 | 0.030 |
Why?
| Mesentery | 1 | 2012 | 32 | 0.030 |
Why?
| Insulin Resistance | 1 | 2014 | 255 | 0.030 |
Why?
| Rural Health Services | 1 | 2015 | 168 | 0.030 |
Why?
| Research Design | 1 | 2015 | 344 | 0.030 |
Why?
| Diet, High-Fat | 1 | 2014 | 214 | 0.030 |
Why?
| Neoplasms, Glandular and Epithelial | 1 | 2012 | 41 | 0.030 |
Why?
| Vascular Endothelial Growth Factor Receptor-3 | 1 | 2012 | 5 | 0.030 |
Why?
| Pregnancy Proteins | 1 | 2012 | 5 | 0.030 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 6 | 0.030 |
Why?
| Socioeconomic Factors | 1 | 2015 | 584 | 0.030 |
Why?
| Angiopoietin-2 | 1 | 2012 | 15 | 0.030 |
Why?
| Angiopoietin-1 | 1 | 2012 | 16 | 0.030 |
Why?
| Ovary | 1 | 2012 | 114 | 0.030 |
Why?
| Ivermectin | 1 | 2012 | 9 | 0.030 |
Why?
| Antiparasitic Agents | 1 | 2012 | 10 | 0.030 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2012 | 30 | 0.030 |
Why?
| Infant | 1 | 2020 | 3575 | 0.020 |
Why?
| Algorithms | 1 | 2015 | 613 | 0.020 |
Why?
| Hydatidiform Mole | 1 | 2011 | 2 | 0.020 |
Why?
| RNA, Messenger | 1 | 2014 | 1099 | 0.020 |
Why?
| Crohn Disease | 1 | 2012 | 90 | 0.020 |
Why?
| Interleukin-6 | 1 | 2012 | 265 | 0.020 |
Why?
| Isoenzymes | 1 | 2011 | 168 | 0.020 |
Why?
| Promoter Regions, Genetic | 1 | 2012 | 467 | 0.020 |
Why?
| Gene Expression | 1 | 2012 | 612 | 0.020 |
Why?
| Risk Assessment | 1 | 2015 | 1255 | 0.020 |
Why?
| Radiography | 1 | 2011 | 485 | 0.020 |
Why?
| Cell Line | 1 | 2012 | 1010 | 0.020 |
Why?
| Cohort Studies | 1 | 2013 | 1403 | 0.020 |
Why?
| DNA Methylation | 1 | 2012 | 544 | 0.020 |
Why?
| Rats | 1 | 2014 | 3273 | 0.020 |
Why?
| Blotting, Western | 1 | 2006 | 587 | 0.020 |
Why?
| Myocardium | 1 | 2006 | 443 | 0.010 |
Why?
| Age Factors | 1 | 2006 | 1092 | 0.010 |
Why?
|
|
Quick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|